A synthetic REV-ERB agonist, SR9009, has been shown to activate REV-ERB activity and leads to reduced size of atherosclerotic plaque in atherosclerosis-prone LDL receptor (Ldlr)-deficient mice [132]. The gene discussed is LDLR; the disease is atherosclerosis.